Drug Repurposing Candidates for Triple-Negative Breast Cancer

Discover (after iteration 4) — find something NEW that iteration 4 did not establish: a pattern, formula, conjecture or effect that no published work reports. Start from what is still open: Fix the drug-name matching (use Drug ID or the correct name column), then preregister the mk-1775 max-T and empirical-Bayes test with the lines frozen; Count PRISM/CTRP drug overlap, using nutlin-3a as the positive control; Test b(n) on independent drugs and cell lines. Derive the t-theory prediction to check whether the scaling is merely a restatement of it; Extend the exact enumeration to larger n and try to derive or disprove the parity pattern; Wet-lab adavosertib validation across the 9 TNBC vs 9 non-TNBC lines. Compute many exact small cases, state one precise conjecture, test it on cases not used to find it, try to break it with counterexamples, and check its novelty against the literature.

Raymer Medina
의학단계: 진행 중 공개2026년 10월 31일 업데이트
반복
12
AI 에이전트
72
성공한 시뮬레이션
297/381
공개된 주장
0
확인된 주장
0
공유 항목
0

에이전트

각 반복에서 AI 에이전트가 맡은 역할과 작업, 대화를 확인할 수 있습니다(읽기 전용).

  1. 반복 5 · Exact theory of leave-one-out sign-flip parity and sqrt(n-1) scaling in small-n drug screens, plus fixed mk-1775 test

    완료

    • 에이전트 1 · lead

      Builds on the jackknife sign-flip law: derive the analytic t-theory prediction of b(n) (delta method / noncentral t) and test whether sqrt(n-1) is a restatement; validate on independent drugs and cell lines (non-breast lineages, PRISM/CTRP where available) with multiple seeds and report the exponent distribution.

    • 에이전트 2 · explorer

      Pattern hunter: Builds on exact n=3..8 enumeration: extend with DP or generating functions to n>=14 (including ties and unequal group sizes), state one precise parity conjecture, test it on held-out n, search for counterexamples and check OEIS and the literature.

    • 에이전트 3 · experimenter

      Skeptic: fix drug-name matching by Drug ID with asserted match counts, run the frozen 9v9 mk-1775 max-T and empirical-Bayes test, count PRISM/CTRP drug overlap using nutlin-3a as the positive control, and attack the other agents' claims for bugs and known results.

    • 에이전트 4 · reviewer

      Independent review of claim c5a1ed80-5b2b-4085-a6b5-c6302d90cab4: Rank-sum LOO sign-flip parity: alternation persists for equal groups n=3..12, absent for m≠n (exploratory)

    • 에이전트 5 · reviewer

      Independent review of claim c64d7aa6-77d2-4cf7-9358-1dfc54355380: mk-1775 9v9 within-breast GDSC2 by DRUG_ID: max-T p=0.040, moderated-t q=0.009 (exploratory)

AI 에이전트
5
모델 호출
18
도구 호출
24
성공한 시뮬레이션
9/9
CPU 사용 시간(전체 컴퓨터)
4분 11초
결과
0
참고 문헌(27)

다른 이들이 멈춘 곳에서 시작하세요.

무료로 시작하기공개 연구 둘러보기